Tatva Chintan breaks ground for new Dahej unit
Tatva Chintan Pharma Chem Ltd conducted the groundbreaking ceremony for its new greenfield unit at Dahej, Gujarat, on July 20, 2026, following Board approval. The expansion entails an investment of ~₹200 crore to add 344 kilolitres of reactor capacity, funded by internal accruals and debt. This move aligns with the company's strong financial performance in Q1FY27, where net profit surged 140% to ₹159.81 million and revenue rose to ₹1,670.55 million.
*this image is generated using AI for illustrative purposes only.
Tatva Chintan Pharma Chem Ltd held the groundbreaking ceremony for its new greenfield manufacturing unit at Dahej - III, Dahej Industrial Estate, Gujarat, on July 20, 2026. This development follows the Board's approval in Q1FY27 to expand capacity to meet growing market demands. The company reported a 140% surge in consolidated net profit to ₹159.81 million for the quarter ended June 30, 2026, supported by a 43% rise in revenue from operations to ₹1,670.55 million.
The new facility at Dahej is part of a strategic expansion involving an investment of ~₹200 crore. It will add a reactor capacity of 344 kilolitres, augmenting the company's existing combined installed capacity of 791 kilolitres at Ankleshwar and Dahej SEZ. The project is expected to be completed within 21 months and will be funded through internal accruals and debt. The Board also approved increasing the company's borrowing limits from ₹300 crore to ₹1,000 crore, subject to shareholder approval.
Key Financial Metrics (Consolidated)
The table below summarises the company's consolidated financial performance for Q1FY27:
| Particulars: | Q1FY27 (Unaudited) | Q1FY26 (Unaudited) |
|---|---|---|
| Revenue from operations | ₹1,670.55 million | ₹1,168.64 million |
| Total income | ₹1,698.35 million | ₹1,180.19 million |
| EBITDA | ₹323 million | ₹173 million |
| EBITDA Margin | 19.33% | 14.80% |
| Profit before tax | ₹211.11 million | ₹91.01 million |
| Net profit | ₹159.81 million | ₹66.51 million |
| Basic EPS (₹10) | ₹6.83 | ₹2.84 |
Segment and Operational Performance
Structure Directing Agents (SDA) contributed 35% of the total revenue in Q1FY27, amounting to ₹578 million. The company remains the 2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India. Phase Transfer Catalyst (PTC) and Electrolyte Salts (ESS) are other key product categories, with exports constituting 75% of revenue in FY25.
Board Decisions and Approvals
The Board approved the unaudited financial results on July 17, 2026. M/s. NDJ & Co., Chartered Accountants, the statutory auditors, issued a Limited Review Report expressing an unmodified opinion. Additionally, the Board sanctioned the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director and Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors for three years from February 1, 2027, subject to shareholder approval.
Historical Stock Returns for Tatva Chintan Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +6.43% | +5.14% | +49.73% | +54.93% | +56.94% | -21.15% |
How will the increased borrowing limits impact the company's leverage ratios and interest coverage in the short to medium term?
What specific market segments are driving the demand for the additional 344 kilolitres of reactor capacity?
Will the reliance on debt funding for the Dahej expansion affect the company's ability to maintain its current dividend payout policy?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
